厄贝沙坦减轻糖尿病肾病大鼠肾损伤

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (4): 506-511.

厄贝沙坦减轻糖尿病肾病大鼠肾损伤

张娅¹, 黄文辉^1*, 侯智敏², 刘菊香¹, 刘静¹

1.甘肃省人民医院, 甘肃兰州 730000;
2.甘肃中医药大学临床医学系, 甘肃兰州 730000

收稿日期:2019-04-12 修回日期:2019-11-04 出版日期:2020-04-05 发布日期:2020-04-06
通讯作者: *huangwh9966@163.com
基金资助:
甘肃省人民医院院内科研基金(17GSSY4-2)

Irbesartan attenuates renal injury with diabetic nephropathy rats

ZHANG Ya¹, HUANG Wen-hui^1*, HOU Zhi-min², LIU Ju-xiang¹, LIU Jing¹

1. Gansu Provincial People's Hospital, Lanzhou 730000;
2. Department of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China

Received:2019-04-12 Revised:2019-11-04 Online:2020-04-05 Published:2020-04-06
Contact: *huangwh9966@163.com

摘要/Abstract

摘要： 目的观察厄贝沙坦能否减轻糖尿病肾病(DN)大鼠的肾损伤。方法将大鼠随机分为对照组、DN模型组、厄贝沙坦治疗组。于22周测体质量、随机血糖、24 h尿微量白蛋白、血肌酐、尿素氮,观察肾脏形态改变。应用荧光定量PCR检测miR-192 mRNA 在大鼠肾组织中的表达;蛋白免疫印迹法、免疫组织化学法检测肾组织TGF-β1、Zeb1、collagen Ⅰ蛋白的表达。结果与对照组比较,DN组大鼠体质量、随机血糖、血肌酐、尿素氮和24 h尿微量白蛋白显著增高(P＜0.05);与DN组比较,厄贝沙坦治疗组大鼠体质量、随机血糖、血肌酐、尿素氮和24 h尿微量白蛋白显著降低(P＜0.05)。厄贝沙坦治疗可以改善DN大鼠的一般情况和肾脏病理损害。与对照组相比,DN组miR-192 mRNA在DN大鼠肾脏的表达下调(P＜0.05);与DN组相比,厄贝沙坦组miR-192 mRNA表达上调(P＜0.05);与对照组大鼠相比,DN组肾组织的TGF-β1、ZEB1和collagen Ⅰ蛋白表达量明显增加(P＜0.05);与DN组相比较,厄贝沙坦治疗可以减少TGF-β1、ZEB1和collagen Ⅰ蛋白的表达(P＜0.05)。结论厄贝沙坦可减轻糖尿病肾病大鼠的肾损伤。

关键词: 糖尿病肾病, miR-192, 厄贝沙坦

Abstract: Objective To observe the effect of Irbesartan on renal injury in diabetic nephropathy (DN) rats. Methods The rats were randomly divided into control group, DN model group and Irbesartan treatment group. At the age of 22 weeks, body weight, random blood sugar, serum creatinine,urea nitrogen,and 24-hour urinary microalbumin were measured.The morphological changes of kidneys were observed. The expression of microRNA-192 in rat kidney was detected by fluorescence quantitative PCR,the expression of TGF-beta 1, Zeb1 and collagen Ⅰ in rat kidney were detected by Western blot and immuno-histochemistry. Results Compared with the control group, the body weight, random blood sugar, serum creatinine,urea nitrogen,and 24-hour urinary micro-albumin of the model group rats increased significantly (P＜ 0.05); Compared with the DN group, the body weight, random blood sugar, serum creatinine,urea nitrogen,and 24-hour urinary micro-albumin of the Irbesartan treatment group rats decreased significantly(P＜0.05). Irbesartan treatment can improve the general condition and renal pathological damage of DN rats. Compared with the normal control group, the expression of microRNA-192 in the kidney of DN rats in the DN model group was down-regulated (P＜0.05), while that in the Irbesartan group was up-regulated (P＜0.05). WB and immuno-histochemical results showed that the expression of TGF-beta 1, ZEB1 and collagen Ⅰ protein in kidney tissue of DN model group was significantly increased as compared with that of normal group (P＜0.05); Compared with DN group, Irbesartan treatment reduced expression of TGF-beta 1, ZEB1 and collagen Ⅰ protein, with statistical significance (P＜ 0.05). Conclusions Irbesartan attenuates renal damage in diabetic nephropathy rats.

Key words: diabetic nephropathy, miR-192, Irbesartan

中图分类号:

张娅, 黄文辉, 侯智敏, 刘菊香, 刘静. 厄贝沙坦减轻糖尿病肾病大鼠肾损伤[J]. 基础医学与临床, 2020, 40(4): 506-511.

ZHANG Ya, HUANG Wen-hui, HOU Zhi-min, LIU Ju-xiang, LIU Jing. Irbesartan attenuates renal injury with diabetic nephropathy rats[J]. Basic & Clinical Medicine, 2020, 40(4): 506-511.

参考文献

[1] Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988—2012[J]. JAMA, 2015,314:1021-1029.
[2] 曹晔, 杨丹, 苏津,等. 糖尿病肾病患者肾素-血管紧张素-醛固酮系统与血流动力学的关系[J]. 临床检验杂志, 2012,30:1004-1005.
[3] 刘红, 韩璐璐, 谢爽,等. 连续口服厄贝沙坦对健康中国志愿者血浆microRNAs表达的影响[C].中国心脏大会, 2011:248-250.
[4]Kantharidis P, Wang B, Carew RM, et al. Diabetes complications: the microRNA perspective[J]. Diabetes, 2011, 60: 1832-1837.
[5]Lan HY, Chung AC. TGF-β/Smad signaling in kidney disease[J]. Semin Nephrol, 2012, 32: 236-243.
[6]Chung AC, Dong Y, Yang W, et al. Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs[J]. Mol Ther, 2013, 21: 388-398.
[7]Kriegel AJ, Liu Y, Cohen B, et al. miR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis[J]. Physiol Genomics, 2012, 44: 259-267.
[8]房勃龙, 韩鸿玲. TGF-β、Smad信号通路蛋白及α-SMA在糖尿病肾病患者肾组织中的表达和意义[J]. 天津医药, 2013,11:1067-1069.
[9]Kantharidis P, Wang B, Carew RM, et al. Diabetes complications: the microRNA perspective[J]. Diabetes, 2011, 60:1832-1837.
[10]Krupa A,Jenkins R,Luo DD,et al.Loss of microRNA-192promotes fibrogenesisindiabetic nephropathy[J].J Am Soc Nephrol,2010,21:438-447.
[11]Kriegel AJ,Fang Y,Liu Y,et al.microRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1:a novel role of miR-382[J].Nucleic Acids Res,2010,38:8338-8347.
[12]Putta S,Lanting L,Sun G,et al.Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy[J].J Am Soc Nephrol,2012,23:458-469.
[13]Zhong X,Chung AC,Chen HY,et al.Smad3-mediated upregulation of miR-21 promotes renalfibrosis[J].J Am Soc Nephrol,2011,22:1668-1681.
[14]Kato M, Arce L, Wang M, et al. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells[J]. Kidney Int, 2011, 80: 358-368.
[15]Lv C, Zhou Y, Wu C, et al. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy[J]. Diabetes Metab Res, 2015, 31: 717-724.